Skip to main navigation Skip to search Skip to main content

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: the PROOF Trial

  • Harris, Marion (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date1/11/19 → 31/10/24

Keywords

  • clinical trial
  • treatment efficacy
  • phase 3 study
  • bile duct cancer

Clinical Trial Phase

  • Phase III (a & b)